GSK (LON:GSK) Shares Cross Above Two Hundred Day Moving Average - What's Next?

Key Points

• GSK's share price has recently crossed above its **200-day moving average** of GBX 1,429.03, indicating potential bullish momentum in the stock.
• Wall Street analysts have mixed opinions on GSK, with target prices ranging from **GBX 1,400 to GBX 2,000**, and a consensus rating of "Hold."
• Insiders have shown confidence in GSK, purchasing shares totaling approximately **£27,192** in recent transactions, representing a modest investment in the company's stock.

GSK plc (LON:GSK - Get Free Report)'s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,429.03 ($19.23) and traded as high as GBX 1,453 ($19.55). GSK shares last traded at GBX 1,451.50 ($19.53), with a volume of 7,559,608 shares.

Analyst Ratings Changes

Several research firms have recently issued reports on GSK. Berenberg Bank restated a "hold" rating and issued a GBX 1,600 target price on shares of GSK in a report on Friday, July 18th. JPMorgan Chase & Co. lowered their target price on shares of GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating for the company in a report on Monday, August 4th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 1,450 target price on shares of GSK in a report on Thursday, July 31st. Finally, Shore Capital reiterated a "buy" rating and set a GBX 2,000 price objective on shares of GSK in a report on Wednesday, July 30th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of GBX 1,612.50.

GSK Stock Performance

The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The firm has a market cap of £60.04 billion, a P/E ratio of 23.90, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The firm's fifty day moving average price is GBX 1,413.36 and its 200 day moving average price is GBX 1,430.10.

GSK (LON:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported GBX 75.30 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts expect that GSK plc will post 175.980975 EPS for the current fiscal year.

Insider Activity at GSK

In other GSK news, insider Wendy Becker acquired 545 shares of the company's stock in a transaction dated Friday, June 20th. The shares were acquired at an average cost of GBX 1,435 per share, with a total value of £7,820.75. Also, insider Jonathan Symonds acquired 1,350 shares of the company's stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of GBX 1,435 per share, for a total transaction of £19,372.50. In the last three months, insiders have acquired 1,913 shares of company stock worth $2,744,669. 1.61% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.